HALO
Price
$60.07
Change
-$1.35 (-2.20%)
Updated
May 1, 04:59 PM (EDT)
Capitalization
7.42B
4 days until earnings call
IDYA
Price
$20.44
Change
+$0.31 (+1.54%)
Updated
May 1, 04:59 PM (EDT)
Capitalization
1.79B
12 days until earnings call
Ad is loading...

HALO vs IDYA

Header iconHALO vs IDYA Comparison
Open Charts HALO vs IDYABanner chart's image
Halozyme Therapeutics
Price$60.07
Change-$1.35 (-2.20%)
Volume$33.41K
Capitalization7.42B
IDEAYA Biosciences
Price$20.44
Change+$0.31 (+1.54%)
Volume$109.48K
Capitalization1.79B
HALO vs IDYA Comparison Chart
Loading...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HALO vs. IDYA commentary
May 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a Buy and IDYA is a Buy.

Ad is loading...
COMPARISON
Comparison
May 02, 2025
Stock price -- (HALO: $61.42 vs. IDYA: $20.13)
Brand notoriety: HALO and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 91% vs. IDYA: 84%
Market capitalization -- HALO: $7.42B vs. IDYA: $1.79B
HALO [@Biotechnology] is valued at $7.42B. IDYA’s [@Biotechnology] market capitalization is $1.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $293.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 2 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • HALO’s FA Score: 2 green, 3 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, HALO is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 7 TA indicator(s) are bullish while IDYA’s TA Score has 5 bullish TA indicator(s).

  • HALO’s TA Score: 7 bullish, 3 bearish.
  • IDYA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, HALO is a better buy in the short-term than IDYA.

Price Growth

HALO (@Biotechnology) experienced а +5.15% price change this week, while IDYA (@Biotechnology) price change was +6.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.98%. For the same industry, the average monthly price growth was +8.35%, and the average quarterly price growth was -7.74%.

Reported Earning Dates

HALO is expected to report earnings on Aug 12, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+2.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($7.42B) has a higher market cap than IDYA($1.79B). HALO YTD gains are higher at: 28.467 vs. IDYA (-21.673). HALO has higher annual earnings (EBITDA): 657M vs. IDYA (-323.14M). IDYA has more cash in the bank: 676M vs. HALO (596M). IDYA has less debt than HALO: IDYA (19.2M) vs HALO (1.51B). HALO has higher revenues than IDYA: HALO (1.02B) vs IDYA (7M).
HALOIDYAHALO / IDYA
Capitalization7.42B1.79B414%
EBITDA657M-323.14M-203%
Gain YTD28.467-21.673-131%
P/E Ratio17.50N/A-
Revenue1.02B7M14,500%
Total Cash596M676M88%
Total Debt1.51B19.2M7,844%
FUNDAMENTALS RATINGS
HALO vs IDYA: Fundamental Ratings
HALO
IDYA
OUTLOOK RATING
1..100
1218
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
2459
SMR RATING
1..100
1149
PRICE GROWTH RATING
1..100
4362
P/E GROWTH RATING
1..100
52100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (63) in the null industry is in the same range as HALO (81) in the Biotechnology industry. This means that IDYA’s stock grew similarly to HALO’s over the last 12 months.

HALO's Profit vs Risk Rating (24) in the Biotechnology industry is somewhat better than the same rating for IDYA (59) in the null industry. This means that HALO’s stock grew somewhat faster than IDYA’s over the last 12 months.

HALO's SMR Rating (11) in the Biotechnology industry is somewhat better than the same rating for IDYA (49) in the null industry. This means that HALO’s stock grew somewhat faster than IDYA’s over the last 12 months.

HALO's Price Growth Rating (43) in the Biotechnology industry is in the same range as IDYA (62) in the null industry. This means that HALO’s stock grew similarly to IDYA’s over the last 12 months.

HALO's P/E Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for IDYA (100) in the null industry. This means that HALO’s stock grew somewhat faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOIDYA
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 8 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
67%
Bearish Trend 16 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
69%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IAXAX8.23N/A
N/A
VY® T. Rowe Price Divers Mid Cap Gr A
PISDX14.88N/A
N/A
Columbia Pyrford International Stock A
ACAEX13.15N/A
N/A
American Century International Gr G
AFJAX20.36N/A
N/A
Virtus NFJ International Value A
FRDPX85.98N/A
N/A
Franklin Rising Dividends A

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+2.18%
IMNM - IDYA
54%
Loosely correlated
+2.93%
RCKT - IDYA
54%
Loosely correlated
+4.81%
GRI - IDYA
54%
Loosely correlated
+0.56%
NTLA - IDYA
53%
Loosely correlated
+7.93%
ETNB - IDYA
52%
Loosely correlated
+6.09%
More